{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:42:03Z","timestamp":1768286523509,"version":"3.49.0"},"reference-count":57,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":607,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Anaesthesiol Scand"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1111\/aas.12253","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T03:23:05Z","timestamp":1388719385000},"page":"143-156","source":"Crossref","is-referenced-by-count":8,"title":["Population pharmacometrics in support of analgesics studies"],"prefix":"10.1111","volume":"58","author":[{"given":"P.","family":"V\u00c4LITALO","sequence":"first","affiliation":[{"name":"School of Pharmacy; University of Eastern Finland; Kuopio Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.-P.","family":"RANTA","sequence":"additional","affiliation":[{"name":"School of Pharmacy; University of Eastern Finland; Kuopio Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"HOOKER","sequence":"additional","affiliation":[{"name":"Uppsala University; Department of Pharmaceutical Biosciences; Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"KOKKI","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Eastern Finland; Kuopio Finland"},{"name":"Kuopio University Hospital; Department of Anesthesia and Operative Services; Kuopio Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"KOKKI","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Eastern Finland; Kuopio Finland"},{"name":"Kuopio University Hospital; Department of Anesthesia and Operative Services; Kuopio Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,2]]},"reference":[{"key":"10.1111\/aas.12253-BIB0001|aas12253-cit-0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev.pa.32.040192.001153","article-title":"Population pharmacokinetics\/dynamics","volume":"32","author":"Sheiner","year":"1992","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"Suppl. 1","key":"10.1111\/aas.12253-BIB0002|aas12253-cit-0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","article-title":"The role of population PK-PD modelling in paediatric clinical research","volume":"67","author":"De Cock","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0003|aas12253-cit-0003","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data","volume":"5","author":"Sheiner","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1111\/aas.12253-BIB0004|aas12253-cit-0004","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF01060053","article-title":"Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data","volume":"8","author":"Sheiner","year":"1980","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1111\/aas.12253-BIB0005|aas12253-cit-0005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/clpt.1991.103","article-title":"Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations","volume":"50","author":"Fattinger","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/aas.12253-BIB0006|aas12253-cit-0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2011.02.056","article-title":"Individualized dosing regimens in children based on population PKPD modelling: are we ready for it?","volume":"415","author":"Knibbe","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1111\/aas.12253-BIB0007|aas12253-cit-0007","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10928-005-0062-y","article-title":"Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science","volume":"32","author":"Pillai","year":"2005","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1111\/aas.12253-BIB0008|aas12253-cit-0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10928-005-9002-0","article-title":"Pharmacokinetic-pharmacodynamic modelling: history and perspectives","volume":"33","author":"Csajka","year":"2006","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1111\/aas.12253-BIB0009|aas12253-cit-0009","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","article-title":"Population pharmacokinetics I: background, concepts, and models","volume":"38","author":"Ette","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1111\/aas.12253-BIB0010|aas12253-cit-0010","first-page":"e6","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"key":"10.1111\/aas.12253-BIB0011|aas12253-cit-0011","first-page":"e38","article-title":"Basic concepts in population modeling, simulation, and model-based drug development - part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"key":"10.1111\/aas.12253-BIB0012|aas12253-cit-0012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","article-title":"Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004","volume":"46","author":"Brendel","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/aas.12253-BIB0013|aas12253-cit-0013","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1111\/aas.12253-BIB0014|aas12253-cit-0014","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2125.1996.04231.x","article-title":"Estimating impossible curves using NONMEM","volume":"42","author":"Schoemaker","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0015|aas12253-cit-0015","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1208\/aapsj070245","article-title":"A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective","volume":"7","author":"Wade","year":"2005","journal-title":"AAPS J"},{"key":"10.1111\/aas.12253-BIB0016|aas12253-cit-0016","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pst.393","article-title":"The time course of drug effects","volume":"8","author":"Al-Sallami","year":"2009","journal-title":"Pharm Stat"},{"key":"10.1111\/aas.12253-BIB0017|aas12253-cit-0017","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2125.2011.03925.x","article-title":"Understanding the time course of pharmacological effect: a PKPD approach","volume":"71","author":"Wright","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0018|aas12253-cit-0018","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00431-006-0188-y","article-title":"Population clinical pharmacology of children: general principles","volume":"165","author":"Anderson","year":"2006","journal-title":"Eur J Pediatr"},{"key":"10.1111\/aas.12253-BIB0019|aas12253-cit-0019","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","article-title":"Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint","volume":"71","author":"Duffull","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0020|aas12253-cit-0020","first-page":"iv","article-title":"The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves","volume":"40","author":"Hill","year":"1910","journal-title":"J Physiol"},{"key":"10.1111\/aas.12253-BIB0021|aas12253-cit-0021","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev.pharmtox.41.1.625","article-title":"Drug treatment effects on disease progression","volume":"41","author":"Chan","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/aas.12253-BIB0022|aas12253-cit-0022","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","article-title":"Tips and traps analyzing pediatric PK data","volume":"21","author":"Anderson","year":"2011","journal-title":"Paediatr Anaesth"},{"key":"10.1111\/aas.12253-BIB0023|aas12253-cit-0023","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/01.anes.0000265151.78943.af","article-title":"Pharmacokinetics and pharmacodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusion","volume":"106","author":"Kim","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1111\/aas.12253-BIB0024|aas12253-cit-0024","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s002280100367","article-title":"Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy","volume":"57","author":"Anderson","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0025|aas12253-cit-0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.2010.03679.x","article-title":"Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic\/pharmacodynamic simulation","volume":"70","author":"Revilla","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0026|aas12253-cit-0026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/aas.12253-BIB0027|aas12253-cit-0027","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/aas.12253-BIB0028|aas12253-cit-0028","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0029|aas12253-cit-0029","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00228-011-1148-7","article-title":"Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children","volume":"68","author":"Viljoen","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0030|aas12253-cit-0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/BF02353466","article-title":"Three new residual error models for population PK\/PD analyses","volume":"23","author":"Karlsson","year":"1995","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1111\/aas.12253-BIB0031|aas12253-cit-0031","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1111\/aas.12253-BIB0032|aas12253-cit-0032","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated covariate model building within NONMEM","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharm Res"},{"key":"10.1111\/aas.12253-BIB0033|aas12253-cit-0033","first-page":"Abstr W4354","article-title":"Full model estimation approach for covariate effects: inference based on clinical importance and estimation precision","volume":"6","author":"Gastonguay","year":"2004","journal-title":"AAPS J"},{"key":"10.1111\/aas.12253-BIB0034|aas12253-cit-0034","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/aas.12253-BIB0035|aas12253-cit-0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1111\/aas.12253-BIB0036|aas12253-cit-0036","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check","volume":"28","author":"Yano","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1111\/aas.12253-BIB0037|aas12253-cit-0037","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1177\/0091270011418658","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children","volume":"52","author":"V\u00e4litalo","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0038|aas12253-cit-0038","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2125.1998.00780.x","article-title":"Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children","volume":"46","author":"Anderson","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0039|aas12253-cit-0039","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/00000542-200606000-00019","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers","volume":"104","author":"Yassen","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1111\/aas.12253-BIB0040|aas12253-cit-0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.clpt.6100025","article-title":"Mechanism-based PK\/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers","volume":"81","author":"Yassen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/aas.12253-BIB0041|aas12253-cit-0041","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/00003088-200746110-00004","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers","volume":"46","author":"Yassen","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/aas.12253-BIB0042|aas12253-cit-0042","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/ecp.11.59","article-title":"Pharmacokineticpharmacodynamic modeling in acute and chronic pain: an overview of the recent literature","volume":"4","author":"Martini","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0043|aas12253-cit-0043","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00003088-200948060-00003","article-title":"Morphine glucuronidation in preterm neonates, infants and children younger than 3 years","volume":"48","author":"Knibbe","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/aas.12253-BIB0044|aas12253-cit-0044","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11536750-000000000-00000","article-title":"Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children","volume":"50","author":"Krekels","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/aas.12253-BIB0045|aas12253-cit-0045","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2125.1996.00481.x","article-title":"Characterization and validation of a pharmacokinetic model for controlled-release oxycodone","volume":"42","author":"Mandema","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0046|aas12253-cit-0046","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/0091270006286433","article-title":"Population pharmacokinetics of oxycodone in children 6 months to 7 years old","volume":"46","author":"El-Tahtawy","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0047|aas12253-cit-0047","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/bja\/aer395","article-title":"Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study","volume":"108","author":"Saari","year":"2012","journal-title":"Br J Anaesth"},{"key":"10.1111\/aas.12253-BIB0048|aas12253-cit-0048","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00228-012-1267-9","article-title":"Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy","volume":"68","author":"Kokki","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0049|aas12253-cit-0049","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1742-7843.2012.00884.x","article-title":"Intravenous oxycodone for pain relief in the first stage of labour - maternal pharmacokinetics and neonatal exposure","volume":"111","author":"Kokki","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/aas.12253-BIB0050|aas12253-cit-0050","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3109\/15360288.2012.702200","article-title":"Population pharmacokinetics of oxycodone in patients with cancer-related pain","volume":"26","author":"Komatsu","year":"2012","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1111\/aas.12253-BIB0051|aas12253-cit-0051","article-title":"Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?","author":"Charles","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1111\/aas.12253-BIB0052|aas12253-cit-0052","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s11095-012-0786-5","article-title":"Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR","volume":"29","author":"Xu","year":"2012","journal-title":"Pharm Res"},{"key":"10.1111\/aas.12253-BIB0053|aas12253-cit-0053","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40262-012-0023-8","article-title":"A population pharmacokinetic and pharmacodynamic study of a peripheral \u03ba-opioid receptor agonist CR665 and oxycodone","volume":"52","author":"Olesen","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/aas.12253-BIB0054|aas12253-cit-0054","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1742-7843.2009.00533.x","article-title":"Optimal design of pharmacokinetic studies","volume":"106","author":"Aarons","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1111\/aas.12253-BIB0055|aas12253-cit-0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/0091270010397731","article-title":"Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin","volume":"52","author":"Hennig","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/aas.12253-BIB0056|aas12253-cit-0056","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/biomet\/84.2.429","article-title":"Optimal design in random-effects regression models","volume":"84","author":"Mentr\u00e9","year":"1997","journal-title":"Biometrika"},{"key":"10.1111\/aas.12253-BIB0057|aas12253-cit-0057","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/00003088-200443090-00004","article-title":"Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children","volume":"43","author":"Kokki","year":"2004","journal-title":"Clin Pharmacokinet"}],"container-title":["Acta Anaesthesiologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faas.12253","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/aas.12253\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T13:11:03Z","timestamp":1716383463000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aas.12253"}},"subtitle":["Fundamentals of population pharmacometrics"],"short-title":[],"issued":{"date-parts":[[2014,1,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1111\/aas.12253","relation":{},"ISSN":["0001-5172"],"issn-type":[{"value":"0001-5172","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,2]]}}}